Madison Park Capital Advisors LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)

Madison Park Capital Advisors LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 558 shares of the company’s stock, valued at approximately $325,000.

A number of other institutional investors have also recently bought and sold shares of LLY. Leavell Investment Management Inc. lifted its holdings in shares of Eli Lilly and Company by 16.9% during the 3rd quarter. Leavell Investment Management Inc. now owns 5,550 shares of the company’s stock valued at $2,981,000 after buying an additional 802 shares during the last quarter. First Affirmative Financial Network lifted its holdings in shares of Eli Lilly and Company by 9.5% during the 3rd quarter. First Affirmative Financial Network now owns 1,010 shares of the company’s stock valued at $542,000 after buying an additional 88 shares during the last quarter. Bard Financial Services Inc. lifted its holdings in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Bard Financial Services Inc. now owns 5,800 shares of the company’s stock valued at $3,115,000 after buying an additional 50 shares during the last quarter. Edmonds Duncan Registered Investment Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 36.4% during the 3rd quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 749 shares of the company’s stock valued at $402,000 after buying an additional 200 shares during the last quarter. Finally, GAM Holding AG lifted its holdings in shares of Eli Lilly and Company by 347.7% during the 3rd quarter. GAM Holding AG now owns 14,213 shares of the company’s stock valued at $7,634,000 after buying an additional 11,038 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded up $14.29 during trading on Tuesday, hitting $745.62. 2,041,595 shares of the stock were exchanged, compared to its average volume of 3,051,032. Eli Lilly and Company has a 1-year low of $370.68 and a 1-year high of $800.78. The company has a market capitalization of $708.46 billion, a price-to-earnings ratio of 128.56, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34. The company’s fifty day simple moving average is $763.89 and its 200-day simple moving average is $664.05. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.09 EPS. Sell-side analysts expect that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on LLY. Barclays raised their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Truist Financial reissued a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 22nd. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Bank of America raised their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Morgan Stanley raised their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.